Advancing Pediatric Healthcare: Legislation, Clinical Trials, and Technological Innovations in Drug Development

被引:0
|
作者
Suresh, Pratheksha [1 ]
Murthannagari, Vivek Reddy [1 ]
Krishnan, Ganesh Gonna Nandhi [1 ]
Shivashankar, Neerej [1 ]
Mullaiventhan, Tholkapiyan [1 ]
机构
[1] JSS Acad Higher Educ & Res, JSS Coll Pharm, Dept Regulatory Affairs, POB 20, Ooty 643001, Tamil Nadu, India
关键词
ClinicalTrials; Pediatric Drug Development; Pediatric Exclusivity; Pediatric Regulations; Healthcare; INFORMED-CONSENT; ETHICAL-ISSUES; MEDICINES; CHILDREN; CHALLENGES;
D O I
10.5530/ijpi.14.3.73
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Historically, there have been constraints on pediatric drug trials, resulting in an absence of authorized medicines for children and a significant reliance on off-label use. Pediatric drug development is critical to addressing the special issues of treating children and adolescents. The lack of authorized pediatric treatments has led to efforts to incentivize and compel pediatric medical research in the United States and Europe. The data collected from the FDA and the EMA databases from 2013 to 2023 were analyzed. Statistical analyses revealed trends and changes in exclusive interventions, and qualitative analyses examined research methodologies specific to pediatrics. Clinical trials play a vital role in closing the knowledge gap and improving pediatric treatment. Recent advancements in technology and research methodologies have helped improve pediatric healthcare and treatment.
引用
收藏
页码:607 / 615
页数:9
相关论文
共 50 条
  • [41] Global Distribution of Clinical Trials on Chimeric Antigen Receptor T-Cells in the Pediatric Population: The Economic Impact on Clinical Trials Development
    Martinez, David A.
    Cely, Fabio Samir Vargas
    Hans, Rhea
    Moreno-Cortes, Eider
    Garcia-Robledo, Juan Esteban
    Franco-Fuquen, Pedro
    Castro, Daniela Alejandra
    Castro, Januario E.
    BLOOD, 2023, 142
  • [42] Dose Ranging in Pediatric Drug Development Trials Submitted to the US FDA 2012-2020
    Lee, Carlton K. K.
    Kwon, Eugenia
    Green, Francis G.
    Kelley, Connor M. I.
    Pham, Jennifer
    Abulwerdi, Gelareh
    Samuels, Sherbet
    Green, Dionna J.
    Burckart, Gilbert J.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2025,
  • [43] Well-Defined and Reliable Clinical Outcome Assessments for Pediatric Crohn Disease: A Critical Need for Drug Development
    Sun, Haihao
    Papadopoulos, Elektra J.
    Hyams, Jeffrey S.
    Griebel, Donna
    Lee, Jessica J.
    Tomaino, Juli
    Mulberg, Andrew E.
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2015, 60 (06) : 729 - 736
  • [44] Underrepresentation of Minorities and Lack of Race Reporting in Ulcerative Colitis Drug Development Clinical Trials
    Sedano, Rocio
    Hogan, Malcolm
    McDonald, Cassandra
    Aswani-Omprakash, Tina
    Ma, Christopher
    Jairath, Vipul
    INFLAMMATORY BOWEL DISEASES, 2022, 28 (08) : 1293 - 1295
  • [45] Antibody–cytotoxic drug conjugates in clinical trials and future perspectives: the development of Trojan horses
    Dimitrios Tryfonopoulos
    memo - Magazine of European Medical Oncology, 2014, 7 (1) : 47 - 49
  • [46] Harnessing formulation and clinical pharmacology knowledge for efficient pediatric drug development: Overview and discussions from M-CERSI pediatric formulation workshop 2019
    Khong, Yuet Mei
    Liu, Jing
    Cook, Jack
    Purohit, Vivek
    Thompson, Karen
    Mehrotra, Shailly
    Cheung, S. Y. Amy
    Hay, Justin L.
    Fletcher, Elimika Pfuma
    Wang, Jian
    Sachs, Hari Cheryl
    Zhu, Hao
    Siddiqui, Akhtar
    Cunningham, Lea
    Selen, Arzu
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2021, 164 : 66 - 74
  • [47] Overcoming barriers to drug development and enrollment in clinical trials for adolescents and young adults with lymphoma
    Toner, Keri
    Allen, Carl E.
    Jain, Shweta
    Kahl, Brad
    Leonard, John
    Wasserstrom, Heather
    Friedberg, Jonathan W.
    Seibel, Nita L.
    Kelly, Kara
    EJHAEM, 2023, 4 (04): : 921 - 926
  • [48] Drug development for rare diseases: a case for patient-centricity, equity, and access to clinical trials
    Allison E. Bowen
    Satish Nargundkar
    Journal of Rare Diseases, 4 (1):
  • [49] Alzheimer's disease, estrogens, and clinical trials: A case study in drug development for complex disorders
    Howell, N
    Dykens, J
    Moos, WH
    DRUG DEVELOPMENT RESEARCH, 2005, 66 (02) : 53 - 77
  • [50] Methodological issues associated with preclinical drug development and increased placebo effects in schizophrenia clinical trials
    Brown, Matt A.
    Bishnoi, Ram J.
    Dholakia, Sara
    Velligan, Dawn I.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (04) : 591 - 604